CAN-107(Beihai Kangcheng)

N/A

Report date: 2022/11/21 19:09:07

Base Information

Drug NameCAN-107(Beihai Kangcheng)
Drug Alias NameCAN107
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionFibroblast growth factor 23 antagonists
TargetsFibroblast growth factor 23
Therapy Area/IndicationsHypophosphatemiaMetabolic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCanbridge Life Sciences LtdWuxi Apptec Co LtdBeihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsHypophosphatemiaMetabolic Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A